In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

Zorifertinib is the first drug in the world to launch a registration clinical trial specifically for advanced NSCLC with CNS metastases and achieve remarkable results. It is also the only* EGFR ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of ...

"I just needed something to mask the pain," she explained. The doctor ordered a scan to be on the safe side, and noticed ...

ORIC Pharmaceuticals (NASDAQ: ORIC) is a small-cap pharma stock. It aims to make a difference with its potentially "best-in-class" treatments. The company’s shares have not had a great year, returning ...

More specifically, it aims to treat exon 20 mutations and other atypical mutations ... 18 saw a 75% or greater reduction in the molecules of the mutant EGFR gene that is causing cancer progression.

He has promised a new “universal tariff” of upwards of 20 percent, additional tariffs on China, and a suite of other measures at odds with the previous free trade consensus. Analysts say that ...

Patients harboring EGFR mutations initially respond well to EGFR–TKIs, but acquired mutations render the patients resistant to the available drugs. These mutations include EGFR T790M point mutation.

Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025 Cash and cash equivalents of $282.9 million as of ...